Genetic Engineering & Biotechnology News

JAN15 2018

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: https://gen.epubxp.com/i/923111

Contents of this Issue

Navigation

Page 7 of 29

6 | JANUARY 15, 2018 | GENengnews.com | Genetic Engineering & Biotechnology News GEN etic Engineering & Biotechnology News Scoop the A revolution is transforming the $10 trillion healthcare landscape, promising greater transparency, improved efficiency, and new ways of delivering care, according to a new book entitled, "MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market" (Productivity Press), written by Harry Glorikian and Malorye Allison Branca. The authors map out many of the changes taking place, describe how they are impacting everyone from patients to researchers to insurers, and outline some pre- dictions for the healthcare industry in the years to come. In an exclusive interview with GEN, Glorikian said the book's main theme is about "how data and technol- ogy will transform the practice of medicine and all the associated industries." When asked for examples, Glorikian noted that patients will be able to monitor their heart health with a KardiaBand (AliveCor) that pairs with your Apple watch so you can detect atrial fibrillation without hav- ing to go to your doctor. Also, artificial intelligence in drug discovery will allow scientists to identify potential therapeutic molecules that were not obvious under typi- cal drug-discovery paradigms. In personalized medicine, he continues, there will be "wholesale change in how oncology departments will be physically organized to manage the data that comes in from tumor samples. Doctors will then be able to assess and tie that data to the appropriate therapy based on hard data and prescribe the right drug to the right patient at the right time." Big Data Is Rapidly Transforming Medicine Climbing Everest to Support Cancer Research DNA Sequencing: Achieved a Milestone On December 14, 2017, the Garvan Insti- tute in Sydney, Australia, acknowledged the achievement of a milestone by some of its researchers on the DNA sequencing front. The institute's researchers, led by Martin A. Smith, Ph.D., head of genomic technologies in the Kinghorn Centre for Clinical Genom- ics, announced on Twitter that they had sequenced a single DNA read of more than one million bases long using the increasingly popular MinION nanopore sequencing de- vice from U.K.-based Oxford Nanopore Technology (ONT). We chatted with Dr. Smith to find out what this really means in the scope of sequencing, what the team se- quenced, and what the lab plans to do next. GEN: What was the most challenging part about getting a read of more than 1 million bases long? Dr. Smith: There are quite a few challenges, but DNA extraction and sample prepara- tion are without a doubt the most challenging steps. Even simple pipetting can shear DNA molecules longer than 100 kilobases (kb), so special sample preparation tricks are required, many of them revisited from the '70s and '80s. High-molecular-weight DNA samples form a big clump of stringy gel-like substance, rather than a liquid, so even mea- suring the concentration of the sample is hard because you cannot pipette small volumes of the highly viscous solution (you almost need scissors). Also, an unexpected challenge from reads this long was data analysis—most software tools have been developed for short (<50 kb) reads, therefore, these ultra-long reads are good at finding bugs in code or problems with memory. GEN: What technical tips do you have for researchers who are also trying to perform long-read nanopore sequencing? Dr. Smith: Cut the tips off your pipettes and follow Nick Loman, Ph.D. (@pathogenomenick) and Joshua Quick (@Scalene) on Twitter! Luke Timmerman is a one-man show. He reports, publishes, and markets his own biotechnology newsletter, the Timmerman Report. Turns out he's also a mountain man. Luke plans to climb Mount Everest this spring to raise money—his goal is $175,000—for the Fred Hutchinson Can- cer Research Center in Seattle. He plans to leave for Nepal in March to begin the 10 weeks of training required to ascend the summit. His body needs time to accli- mate to the altitude and to produce more oxygen-ferrying red blood cells. Although Luke has already scaled the highest peaks in North and South America (De- nali and Aconcagua, respectively), he is currently running and bicycling and carry- ing a heavy training backpack uphill to get in tip-top shape. Spon- sors are covering his climbing fees, but he is paying for all his personal expenses, including the flight to Kathmandu. In addition to being an avid climber who wants to tackle the baddest moun- tain on the planet, Luke is also driven by his desire to support cancer research, much of which he has written about over the past 15 years. "I see a cancer revolution happening. Immunotherapies are emerging that use our own immune system to attack can- cer cells, fighting off cancer like we fight off a flu," he writes. "That's amazing. Advances make it possible to detect can- cer earlier than ever before, when it's most easily treated. A cure for cancer has long been their [research- ers'] Everest." We at GEN wish him Godspeed and good luck. Luke Timmerman You can read the full interview with Martin A. Smith, Ph.D., online: http://bit.ly/2pO4Fv5

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - JAN15 2018